Mallinckrodt (MNK) Mentioned Cautiously at Citron Research

(Updated - November 16, 2016 11:42 AM EST)

Mallinckrodt (NYSE: MNK) was mentioned cautiously at Citron Research. The report said a newly published Medicare dashboard proves that:

• "1. As insurance companies have clamped down on reimbursement, tax-inverted Mallinckrodt has dug deeper into the pockets of taxpayer-funded Medicare to peddle its medically unproven Acthar
• 2. The CEO of MNK has committed FRAUD by lying to the investing public about the company’s dependence on the Medicare system.
• 3. Acthar is now THE MOST EXPENSIVE drug reimbursed by Medicare.

You May Also Be Interested In

• Reddit (RDDT) added to S&P 500
• Planet Green halted again, now up 793%
• Quantum Cyber sues White Diamond Research and Stocktwits over short-sell report